Hamid Eskandari, MD
Geriatric Medicine · Foothill Ranch, CANPI 1063662682
Payments from drug & device makers
Across 58 payments — averaging $30.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$189
- Teva Pharmaceuticals USA, Inc.$186
- Sunovion Pharmaceuticals Inc.$131
- Otsuka America Pharmaceutical, Inc.$117
- AbbVie$115
- Indivior Inc.$114
- plus $915 from 16 others
What the payments were for
- Food & beverage$1,767100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $189 |
| Teva Pharmaceuticals USA, Inc. | 6 | $186 |
| Sunovion Pharmaceuticals Inc. | 6 | $131 |
| Otsuka America Pharmaceutical, Inc. | 1 | $117 |
| AbbVie | 1 | $115 |
| Indivior Inc. | 1 | $114 |
| Johnson & Johnson | 5 | $109 |
| Alkermes, Inc. | 1 | $107 |
| AstraZeneca | 4 | $91 |
| Novartis | 6 | $88 |
| Lundbeck LLC | 4 | $79 |
| Lilly USA, LLC | 3 | $71 |
| CMP Pharma, Inc. | 3 | $70 |
| Merck | 3 | $53 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Lucid Diagnostics Inc. | 2 | $42 |
| Inari Medical, Inc. | 1 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Novo Nordisk | 1 | $29 |
| Smith+Nephew | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,767 in reported general payments places this provider in the 80th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 574 | $242,576 |
| JanuviaSitagliptin Phosphate | 149 | $158,550 |
| LinzessLinaclotide | 163 | $151,046 |
| EnbrelEtanercept | 34 | $116,210 |
| JardianceEmpagliflozin | 126 | $99,885 |
| OzempicSemaglutide | 94 | $98,197 |
| VascepaIcosapent Ethyl | 169 | $97,419 |
| MyrbetriqMirabegron | 140 | $94,016 |
| ProliaDenosumab | 54 | $93,126 |
| IngrezzaValbenazine Tosylate | 24 | $89,342 |
| XareltoRivaroxaban | 202 | $84,727 |
| RestasisCyclosporine | 36 | $59,989 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $52,222 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 39 | $48,072 |
| TrulicityDulaglutide | 31 | $41,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Restasis, Creon, Namzaric | $115 | $266,403228 claims |
| AmgenEnbrel, Prolia | $189 | $209,33688 claims |
| MerckJanuvia, Belsomra | $53 | $180,626197 claims |
| Novo NordiskOzempic | $29 | $98,19794 claims |
| Johnson & JohnsonXarelto | $109 | $84,727202 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $71 | $61,60152 claims |
| AstraZenecaFarxiga, Brilinta | $91 | $21,09742 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $131 | $18,16516 claims |
| Indivior Inc.Suboxone | $114 | $12,78945 claims |
| Smith+NephewSantyl | $22 | $8,17524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Foothill Ranch
- Paul AisenSan Diego$15.7M
- Kanagaratnam SivalingamLancaster$2.4M
- Wayne ChenLos Angeles$2M
- Robert FeldmanLaguna Hills$1.9M
- Isabel PereiraFountain Valley$1.2M
- Timothy ParenteauOakland$221K
- Oscar ChienSan Gabriel$208K
- Anna ChangSan Francisco$170K
- Anders NybergSan Diego$163K
- Christopher SalemIrvine$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.